Patients
erythema
ACTIVE TUBERCULOSIS, ACUTE INFECTIONS, ERYTHEMA, VIRAL HEPATITIS, INFLAMMATORY DISEASE
Eligible patients were aged 20 years or older and diagnosed with GPP or EP. Patients with GPP were diagnosed at least 60 days before informed consent was obtained, based on the Japanese Dermatological Association (JDA) criteria, and had an erythema area with pustules accounting for ≥10% of their body surface area and a JDA total severity score < 14. Patients with EP had inflammatory erythema accounting for ≥80% of their body surface area at screening. All patients with GPP or EP were candidates for systemic or phototherapy per the investigator's clinical judgment. Patients who had previous risankizumab exposure, medication‐induced or medication‐exacerbated EP, chronic or relevant acute infections (e.g., HIV, viral hepatitis, active tuberculosis), or other active ongoing inflammatory diseases that could potentially confound trial evaluations were excluded from the study.